Trihexyphenidyl is an antispasmodic drug used as an adjunct drug in the management of parkinsonism and as a treatment for extrapyramidal symptoms caused by drugs affecting the central nervous system (CNS). Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.
- Mechanism
- Curator reviewed · 6 references
Trihexyphenidyl is a non-selective muscarinic acetylcholine receptor antagonist but binds with higher affinity to the M1 subtype. In vivo studies have shown that trihexyphenidyl demonstrates higher affinity for central muscarinic receptors located in the cerebral cortex and lower affinity for those located peripherally. Other studies suggest that trihexyphenidyl may modify nicotinic acetylcholine receptor neurotransmission, leading indirectly to enhanced dopamine release in the striatum. Although the anticholinergic has proven to be useful in the treatment of symptoms associated with Parkinson’s disease or other movement disorders, its mechanism of action has yet to be fully elucidated.
- Primary indication
- Tihexyphenidyl is indicated as an adjunct in the treatment of parkinsonism, an adjuvant in the treatment of parkinsonism with levodopa, and in the control of extrapyramidal disorders caused by central nervous system drugs.Curator reviewed · 8 structured indications
- Formula / weight
- C20H31NO · 301.4662 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1987
- Code names
- Win 511
Resolves to
HWHLPVGTWGOCJO-UHFFFAOYSA-NSMILESOC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Trihexyphenidyl, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account